615 Dupilumab elicits rapid and sustained improvements in itch in adults with moderate-to-severe atopic dermatitis

Itch is the most bothersome symptom of atopic dermatitis (AD). Improvement in itch is an important marker of treatment benefit in AD patients. In dupilumab (DPL) phase 3, double-blind, placebo (PBO)-controlled trials, we assessed intensity and frequency of itch using Peak Pruritus Numerical Rating Scale (PP-NRS), Scoring AD (SCORAD) itch Visual Analog Scale (VAS), and Patient-Oriented Eczema Measure (POEM) itch item, in adults with moderate-to-severe AD who received DPL 300mg every 2 weeks (q2w) or PBO monotherapy (pooled SOLO 1&2: NCT02277743, NCT02277769; 16-week [Wk]), or combined with topical corticosteroids (CHRONOS: NCT02260986, 52Wk; CAF É: NCT02755649, 16Wk).

Source: Journal of Investigative Dermatology - April 19, 2019 Category: Dermatology Authors: J.I. Silverberg, L. Eckert, G. Yosipovitch, B. Kim, E.L. Simpson, A.B. Rossi, M. Ardeleanu, Z. Chen, M. Kaur, A. Gadkari Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research